B+
Bull case
20%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
KMDA
KamadaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 revenue rose 23% year over year to $54.9 million and adjusted EBITDA rose 29% to $14.1 million, driven chiefly by KEDRAB, VARIZIG and HEPAGAM. Commercial growth and initial plasma-supply sales could support affirmed 2026 guidance.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
A director reported September open-market sales; these Form 4 transactions do not establish operating weakness. [#SEC-FORM4-2026-09-11] [#SEC-FORM4-2026-09-17]
Momentum
91
Value
65
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.60 · Bull $10.00 · Bear $5.80Analysis 2026-10-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $13.50
Why
Momentum91 · Δ7d +0.4
Value65 · Δ7d -0.2
Sentiment51 · Δ7d +12.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • A director reported September open-market sales; these Form 4 transactions do not establish operating weakness. [#SEC-FORM4-2026-09-11] [#SEC-FORM4-2026-09-17]
- • CYTOGAM post-marketing findings do not establish a dated commercial milestone or quantified sales uplift. [#IR-2026-08-12]
- • First-half gross margin declined to 42% from 45% year over year.
Catalyst clock
2026-12-31
Q4 plasma-supply sales
Lead driver: Value · See fundamentals
Momentum
91
8% active weight
Current posture
7d trendImproving
Δ7d
+0.4
Δ21d
-
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.0
Sentiment
51
45% active weight
Current posture
7d trendImproving
Δ7d
+12.3
Δ21d
-
Why this grade
Composite grade A. Momentum 91.2 / Value 64.7 / Sentiment 50.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-06. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$7.60
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$5.80
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$452.34M
Beta
0.94
Shares Out
57.69M
P/E (TTM)
20.6
P/S (TTM)
2.39
P/FCF (TTM)
22.79
Rev YoY
+22.7%
EPS YoY
+25.1%
Gross Margin
+40.8%
Op Margin
+14.5%
Net Debt
-$63.91M
Current Ratio
4.06
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data